Results 211 to 220 of about 104,915 (286)

Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. [PDF]

Expert Opin Investig Drugs, 2015
Anand K, Sabbagh M.
europepmc   +1 more source

The Expanding Role of Gene Sequencing in Shaping Fetal Therapies: Clinical and Ethical Considerations

Prenatal Diagnosis, EarlyView.
ABSTRACT In utero interventions are transformative in addressing genetic and anatomic conditions during fetal development. Next generation sequencing enables early genetic testing, playing a pivotal role in prenatal decision‐making by supporting risk stratification, precise and timely diagnosis, which directly informs eligibility for fetal surgical and
Matthew A. Shear, Beltran Borges, Billie R. Lianoglou, Tony Lum, Emma Canepa, Jennifer L. Cohen, Julia E. H. Brown, Akos Herzeg   +7 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Early investigational drugs for hearing loss. [PDF]

Expert Opin Investig Drugs, 2015
Mukherjea D, Ghosh S, Bhatta P, Sheth S, Tupal S, Borse V, Brozoski T, Sheehan KE, Rybak LP, Ramkumar V.   +9 more
europepmc   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry   +4 more
wiley   +1 more source

Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. [PDF]

Expert Opin Investig Drugs, 2015
Kim EJ, Semrad TJ, Bold RJ.
europepmc   +1 more source

Old Legacies and New Paradigms: Confusing Research and Treatment and its Consequences in Responding to Emergent Health Threats [PDF]

, 2005
Javitt, Gail H.
core   +1 more source

Safety of 12‐Months Administration of Ashwagandha (Withania somnifera) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study

Phytotherapy Research, EarlyView.
ABSTRACT Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults (N = 191)
Jaising Salve, Sanjeev Kale, Banwari Lal Prajapati, Adele Sparavigna, Mark Savant, John Ademola, Deepak Langade   +6 more
wiley   +1 more source

Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period. [PDF]

Ther Innov Regul Sci, 2016
Jarow JP, Lemery S, Bugin K, Khozin S, Moscicki R.   +4 more
europepmc   +1 more source